DEFECTIVE EXPRESSION OF INTERFERON-GAMMA, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, TUMOR-NECROSIS-FACTOR-ALPHA, AND INTERLEUKIN-6 IN ACTIVATED PERIPHERAL-BLOOD LYMPHOCYTES FROM GLIOMA PATIENTS
F. Urbani et al., DEFECTIVE EXPRESSION OF INTERFERON-GAMMA, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, TUMOR-NECROSIS-FACTOR-ALPHA, AND INTERLEUKIN-6 IN ACTIVATED PERIPHERAL-BLOOD LYMPHOCYTES FROM GLIOMA PATIENTS, Journal of interferon & cytokine research, 15(5), 1995, pp. 421-429
The ability of a mannoprotein antigen from Candida albicans (MP) or in
terleukin-2 (IL-2) to induce cytokines in cultures of peripheral blood
mononuclear cells (PBMC) of glioma patients and healthy controls was
evaluated by mRNA expression and by protein secretion. The subjects st
udied were all responsive to both MP and IL-2, as assayed by lymphopro
liferation of PBMC cultures. In control subjects, MP and IL-2 were str
ong inducers of IFN-gamma, IL-1 beta, TNF-alpha, and GM-CSF mRNA expre
ssion, but only MP was able to induce considerable levels of IL-6 and
IL-2 mRNA expression. In MP-activated PBMC from glioma subjects, a hig
hly defective IFN-gamma, together with a significant reduction in TNF-
gamma and GM-CSF mRNA expression, was observed. This impairment was pa
ralleled by a decreased accumulation of IL-6 and IL-2 mRNA. The patter
n of cytokine mRNAs in IL-2-activated PBMC of glioma patients confirme
d the impairment of IFN-gamma mRNA expression paralleled by a reductio
n in IL-6, TNF-alpha and GM-CSF mRNA, compared with healthy subjects.
Coherently, in PBMC cultures from glioma patients, there was a clear-c
ut decrease in the secretion of IL-6 and TNF-alpha and especially of I
FN-gamma compared with healthy controls. No or very low levels of IL-4
, IL-10, and TGF-beta(2) mRNA expression were detected in PBMC culture
s of both glioma and control populations, irrespective of the activati
on conditions. Considering the cytokine network and the key, pivotal r
ole played by IFN-gamma in the activation of antitumor cytotoxicity, w
e suggest that a defective IFN-gamma production can be a key immunolog
ic defect in glioma patients.